Sulodexide

Drug Profile

Sulodexide

Alternative Names: 3GS; Glucoronylglucosaminoglycan sulphate; KRX-101; Sulodexide Gelcaps; Sulonex; Vessel

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; Keryx Biopharmaceuticals
  • Class Antihyperlipidaemics; Antithrombotics; Glycosaminoglycans
  • Mechanism of Action Glycosaminoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombosis; Vascular disorders
  • Phase III Venous insufficiency; Venous thromboembolism
  • Discontinued Diabetic nephropathies; Glomerulonephritis; Kidney disorders; Pulmonary fibrosis

Most Recent Events

  • 12 Dec 2017 Alfa Wassermann Tunisia in collaboration with Poseidon CRO plans the AWAOMI2 phase III trial for Peripheral Arterial Obstructive Disease in Tunisia , (NCT03370705)
  • 19 Sep 2016 Phase-III clinical trials in Venous insufficiency in Poland (PO) (EudraCT2016-000783-42)
  • 27 Mar 2008 Discontinued - Phase-III for Diabetic nephropathies in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top